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Knee osteoarthritis (KOA), a common disabling disease with a high impact on quality of life, has a large societal cost. Yet no procedure halts progressive degeneration 
of the osteoarthritic knee joint.1,2
According to Barry,3 mesenchymal stem cells (MSCs) dif-
ferentiate into many different connective tissue cells, including 
cartilage. MSCs can be isolated from bone marrow, skeletal 
muscle, fat, and synovium. MSCs are multipotent cells with the 
capacity for self-renewal. Therefore, adult MSCs may regener-
ate tissues damaged by disease. In OA, the proliferative capacity 
and ability to differentiate are reduced in MSCs. Intra-articular 
injections of MSCs (MSC therapy) could repair progressively 
degenerated knee cartilage.
This review article summarizes the knowledge on the role 
of intra-articular injections of MSCs in the treatment of KOA, 
based on studies published in PubMed and the Cochrane Li-
brary. The article also reviews the methodology and results of 
the animal and clinical studies published so far on the topic.
Materials and Methods
PubMed (Medline) and the Cochrane Library were searched 
for literature on the role of MSC therapy in treating KOA. The 
key words used were stem cells and knee osteoarthritis. The period 
searched was from when these search engines began until 
January 31, 2014. One hundred thirty-five articles (including 
negative studies) were found, but only the 25 deeply focused 
on the topic were reviewed. The Figure shows the flow dia-
gram of this study.
Results
Several experimental models of KOA have shown that MSC 
therapy can delay progressive degeneration of the knee joint 
(Appendix 1).4-15 Using a rabbit massive meniscal defect 
model, Hatsushika and colleagues13 found that a single intra-
articular injection of synovial MSCs into the knee adhered 
around the meniscal defect and promoted meniscal regenera-
tion. Park and colleagues14 conducted an experimental study 
in dogs—the first demonstrating regional and systemic safety 
and systemic immunomodulatory effects of repeated local 
delivery of allogeneic MSCs in vivo. Regarding the observed 
systemic immunomodulatory effects, clinical and pathologic 
examinations revealed no severe consequences of repeated 
MSC transplantations. Results of mixed leukocyte reactions 
demonstrated suppression of T-cell proliferation after MSC 
transplantations. 
Of the human studies published so far, only 3 were pro-
spective randomized trials (level II evidence) included in the 
Cochrane Library (Appendix 2).16-18 Varma and colleagues16 
found that intra-articular injections of MSCs considerably im-
proved overall KOA outcome scores. Fifty patients with mild to 
moderate KOA were divided into 2 groups. Group A underwent 
arthroscopic débridement, and group B had buffy coat (MSC 
concentrate) injection and arthroscopic débridement. Patients 
were assessed on the basis of their visual analog scale (VAS) 
pain scores and osteoarthritis outcome scores.
Wong and colleagues17 analyzed 56 knees in 56 patients 
(mean age, 51 years) with unicompartmental KOA and genu 
varum. Patients were randomly assigned to 2 groups, MSC and 
control. All patients underwent high tibial osteotomy (HTO) 
and microfracture. Patients in the MSC group received intra-
articular injection of cultured MSCs with hyaluronic acid (HA) 
3 weeks after surgery. Patients in the control group received 
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only HA. The primary outcome measure was Internation-
al Knee Documentation Committee (IKDC) score 6 months, 
1 year, and 2 years after surgery. Secondary outcome measures 
were Tegner and Lysholm clinical scores and 1-year postopera-
tive Magnetic Resonance Observation of Cartilage Repair Tissue 
(MOCART) scores. Both treatment arms achieved improve-
ments in Tegner, Lysholm, and IKDC scores. After adjustment 
for age, baseline scores, and time of evaluation, the MSC group 
had significantly better scores. One year after surgery, magnetic 
resonance imaging (MRI) scans showed significantly better 
MOCART scores for the MSC group. Intra-articular injection 
of MSCs appeared to be effective in improving short-term 
clinical and MOCART outcomes in patients who underwent 
HTO and microfracture for varus knees with cartilage defects.
Saw and colleagues18 compared histologic and MRI evalua-
tion of articular cartilage regeneration in patients with chon-
dral lesions treated by arthroscopic subchondral drilling fol-
lowed by postoperative intra-articular injections of HA with 
and without peripheral blood stem cells (PBSCs). Fifty patients 
(ages, 18-50 years) with International Cartilage Repair Soci-
ety grades 3 and 4 lesions of the knee joint underwent ar-
throscopic subchondral drilling; 25 patients were randomized 
to the intervention group (HA + PBSC) and 25 to the control 
group (HA). Both groups received 5 weekly injections starting 
1 week after surgery. Three additional injections of either HA + 
PBSC or HA only were given at weekly intervals 6 months after 
surgery. After arthroscopic subchondral drilling into grades 3 
and 4 chondral lesions, postoperative intra-articular injections 
of autologous PBSC combined with HA resulted in improved 
quality of articular cartilage repair over the same treatment 
without PBSC.
The other human studies analyzed had a low level of evi-
dence (grade IV, case series) but found that intra-articular 
injections of MSCs reduced pain and improved function in 
patients with KOA over the short term, 1 year (Appendix 3).19-25 
Discussion
This review aimed to define the role of MSC therapy in the 
treatment of KOA. MSC therapy has yielded encouraging out-
comes in experimental models of KOA.4-15 These experimental 
studies have suggested that MSCs can halt cartilage degenera-
tion in KOA. So far, however, only 3 human studies with grade 
II evidence (randomized prospective trials) have been reported 
on the role of MSCs in KOA, but results of these studies have 
suggested that MSCs can reduce pain and improve function.16-18 
Previous reviews of the literature1,2 have analyzed the role 
of MSC therapy in KOA. Barry and Murphy1 reported that sev-
eral early-stage clinical trials, initiated or under way in 2013, 
were testing MSC delivery as an intra-articular injection into 
the knee, but optimal dose and vehicle were yet to be estab-
lished. Filardo and colleagues2 reported that, despite growing 
interest in this biological approach to cartilage regeneration, 
knowledge on the topic is still preliminary, as shown by the 
prevalence of preclinical studies and the presence of low-
quality clinical studies.
Study design weakness prevents effective comparison of 
the efficacy of MSC therapy with that of other treatments for 
relief of pain and other outcomes in KOA. The consistency 
of evidence of the clinical studies is low because of many 
uncontrolled variables.1-3
Conclusion
The results of MSC therapy in KOA are encouraging. However, 
optimal dose and vehicle are yet to be established.1 Knowledge 
on this topic is still preliminary. Many aspects have to be opti-
mized, and further randomized controlled trials are needed to 
Figure. Flow diagram used in this study.
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support the potential of this biological treatment for cartilage 
repair and to evaluate advantages and disadvantages with re-
spect to the available treatments. The relative short duration of 
these studies is also a limitation for the technique at present.
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Appendix 1. Experimental Studies on the Role of Stem Cells in Knee Osteoarthritis
Study Year
Experimental 
Model Method Results Conclusions
Murphy et al4 2003 Goat Adult stem cells were isolated 
from caprine bone marrow, 
expanded in culture, and 
transduced to express green 
fluorescent protein. OA was 
induced unilaterally in the 
knee joint of donor animals 
by complete excision of the 
medial meniscus and resec-
tion of the ACL. After 6 weeks, 
a single dose of 10 million 
autologous cells suspended 
in a dilute solution of sodium 
hyaluronan was delivered to 
the injured knee by direct 
intra-articular injection. Control 
animals received sodium hyal-
uronan alone.
In cell-treated joints, there was 
evidence of marked regenera-
tion of the medial meniscus, 
and implanted cells were 
detected in the newly formed 
tissue. Degeneration of the 
articular cartilage, osteophytic 
remodeling, and subchondral 
sclerosis were reduced in cell-
treated joints compared with 
joints treated with vehicle alone 
(no cells). There was no evi-
dence of repair of the ligament 
in any of the joints.
Local delivery of adult MSCs 
to injured joints stimulates 
regeneration of meniscal tissue 
and retards the progressive 
destruction normally seen in 
this OA model.
Al Faqeh et al5 2008 Sheep Sheep BMSCs were cultured 
in medium containing 5 ng/
mL TGF-β3 + 50 ng/mL IGF-1 
for 3 weeks. The cultured cells 
were then suspended at a 
density of 2×106 cells/mL and 
injected intra-articularly into the 
osteoarthritic knee joint. After 
6 weeks, the distal head of the 
femur and the proximal tibial 
plateau were removed and 
stained with H&E.
The results indicated that knee 
joints treated with autologous 
BMSCs cultured in chondro-
genic medium showed clear 
evidence of articular cartilage 
regeneration in comparison 
with other groups.
Knee joints treated with autolo-
gous BMSCs cultured in chon-
drogenic medium showed clear 
evidence of articular cartilage 
regeneration in comparison 
with other groups.
Grigolo et al6 2009 Rabbit Rabbit knee joints were bilat-
erally subjected to ACL tran-
section to surgically induce 
OA. After 8 weeks, the time 
necessary for development of 
cartilage surface damage, ani-
mals were treated with MSCs 
seeded onto Hyaff-11 scaffold 
in the left condyle and unseed-
ed Hyaff-11 in the contralateral 
knee. Untreated rabbits were 
used as controls. All animals 
were sacrificed 3 or 6 months 
after surgery. Histologic, his-
tomorphometric, and immu-
nohistologic evaluations were 
performed.
OA changes developed in 
all animals subjected to ACL 
transection. The predominant 
macroscopically observed 
OA changes were mild (lateral 
femoral condyle) or moderate 
(medial femoral condyle) ulcer-
ations. Statistically significant 
differences in the quality of 
the regenerated tissue were 
found between the implants 
with scaffolds carrying MSCs 
compared with implants with 
the scaffold alone or controls in 
particular at 6 months.
From the observations, it is 
possible to demonstrate that 
Hyaff-11 (a hyaluronan-based 
scaffold) has potential for MSC 
implantation and may have 
application for the treatment of 
early OA in humans.
Toghraie et al7 2011 Rabbit In this study, scaffold-free 
MSCs obtained from an 
infrapatellar fat pad in an exper-
imental animal model of OA by 
direct intra-articular injection 
were used. MSCs were iso-
lated from a 2.8-kg white New 
Zealand rabbit. The cells were 
expanded and grown in vitro. 
OA was induced by unilateral 
ACL transection of knee joints. 
Twelve weeks after surgery, a 
single dose of 1 million cells 
suspended in 1 mL of medium 
was delivered to the injured 
knee by direct intra-articular 
injection. A control group 
received 1 mL of medium 
without cells. The knees were 
examined 16 and 20 weeks 
after surgery. Repair was inves-
tigated radiologically, grossly, 
and histologically with H&E, 
safranin-O, and toluidine blue 
stains.
Radiologic assessment con-
firmed development of OA 
changes after 12 weeks. 
Rabbits that received MSCs 
showed a lower degree of car-
tilage degeneration, osteophyte 
formation, and subchondral 
sclerosis than the control group 
20 weeks after surgery. Quality 
of cartilage was significantly 
better in the cell-treated group 
than in the control group after 
20 weeks.
Infrapatellar fat pad–derived 
MSCs could be the promising 
cell source for the treatment 
of OA.
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Study Year
Experimental 
Model Method Results Conclusions
Sato et al8 2012 Guinea pig Commercially available human 
MSCs were cultured, labeled 
with CFDA-SE, suspended in 
either PBS or HA, and injected 
into the knee joints of 7-month-
old animals. Control animals 
were injected with either PBS 
or HA alone. The animals were 
sacrificed 1, 3, or 5 weeks 
after transplantation, the knee 
joints were harvested, and fluo-
rescent microscopic analysis 
was performed. Histologic and 
immunohistochemical analyses 
were performed 5 weeks after 
transplantation.
Five weeks after transplanta-
tion, partial cartilage repair 
was noted in the HA-MSC 
group but not in the other 
groups. Examination of CFDA-
SE–labeled cells revealed 
migration, differentiation, and 
proliferation of MSCs in the 
HA-MSC group. There was 
strong immunostaining for type 
II collagen around both residual 
chondrocytes and transplanted 
MSCs in the OA cartilage. This 
scaffold-free, technically unde-
manding technique appears 
to result in the regeneration of 
articular cartilage in the sponta-
neous OA animal model. 
The findings suggested that 
intra-articular injection of the 
HA-MSC mixture is potentially 
beneficial for OA, but further 
study of the long-term effects 
of transplantation is necessary.
Suhaeb et al9 2012 Rat This study aimed to examine 
the effects of MSCs, HA, and 
the combination of MSCs 
and HA in treating OA in a rat 
model.
The histologic observations 
using the O’Driscoll score indi-
cate that use of MSCs and HA 
independently, and not their 
combined use, delays OA pro-
gression.
Results of this preliminary 
study suggested that use of 
either MSCs or HA effectively 
reduces OA progression better 
than their combined use.
Al Faqeh et al10 2012 Sheep Sheep BMSCs were isolated 
and divided into 2 groups. One 
group was cultured in chondro-
genic media containing (Ham’s 
F12:DMEM, 1:1) FD + 1% FBS 
+ 5 ng/mL TGF-β3 + 50 ng/mL 
IGF-1 (CM), and the other was 
cultured in the basal media, FD 
+ 10% FBS (BM). The proce-
dure for surgically induced OA 
was performed on the donor 
sheep 6 weeks before intra-
articular injection into the knee 
joint of a single dose of BMSCs 
from either group, suspended 
in 5 mL FD at a density of 2 
million cells/mL. Control groups 
were injected with basal media 
(no cells).
Six weeks after injection, 
gross evidence of retardation 
of cartilage destruction was 
seen in the osteoarthritic knee 
joints treated with CM as well 
as BM. No significant ICRS 
scoring was detected between 
the 2 groups with cells. 
Macroscopically, however, 
meniscus repair was observed 
in the knee joint treated with 
CM. Severe OA and meniscal 
injury were observed in the 
control group. Interestingly, the 
CM group demonstrated good 
cartilage histoarchitecture, 
thickness, and quality, compa-
rable to those of normal knee 
joint cartilage.
Intra-articular injection of a sin-
gle dose of BMSCs, chondro-
genically induced or not, could 
retard progression of OA in a 
sheep model, but the induced 
cells had better results, particu-
larly in meniscus regeneration.
Toghraie et al11 2012 Rabbit OA was induced in adult white 
New Zealand rabbits by uni-
lateral ACL transection. The 
contralateral knee was consid-
ered the sham-operated group. 
Twelve weeks after surgery, the 
ASC-treated group was inject-
ed intra-articularly with a single 
dose of 1×106 cells suspended 
in 1 mL of medium. The con-
trol group received 1 mL of 
medium without cells, and the 
sham-operated group received 
no treatment. All rabbits were 
sacrificed 16 or 20 weeks 
after surgery. OA progression 
was evaluated radiologically, 
grossly, and histologically with 
H&E, safranin-O, and toluidine 
blue stain.
Twelve weeks after surgery, 
all knees subjected to ACL 
transection showed radio-
logic signs of OA. The findings 
showed significant differences 
in cartilage quality between the 
ASC-injected group and the 
control group, particularly 20 
weeks after surgery.
Results of this study suggested 
that ASCs from subcutaneous 
adipose tissue could be a via-
ble approach for treating OA.
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Study Year
Experimental 
Model Method Results Conclusions
ter Huurne et al12 2012 Mouse ASCs were isolated from 
fat surrounding the inguinal 
lymph nodes and cultured for 
2 weeks. Experimental OA 
was induced by injecting col-
lagenase into the knee joints of 
C57BL/6 mice. OA phenotypes 
were measured within 8 weeks 
after induction. Histologic 
analysis was performed, and 
synovial thickening, entheso-
phyte formation, and cartilage 
destruction were measured 
in the knee joint. ASCs were 
injected into the knee joints 
of mice 7 days after induction 
of collagenase-induced OA. 
On day 1, green fluorescent 
protein-labeled ASCs were 
attached to the lining layer 
in close contact with macro-
phages.
Thickening of synovial lining, 
formation of enthesophytes 
associated with medial col-
lateral ligaments, and formation 
of enthesophytes associated 
with cruciate ligaments were 
significantly inhibited on day 42 
after ASC treatment, by 31%, 
89%, and 44%, respectively. 
Cartilage destruction was inhib-
ited on day 14 (65%) and day 
42 (35%). In contrast to early 
treatment, injection of ASCs on 
day 14 after OA induction had 
no significant effect on synovial 
activation or joint pathology on 
day 42.
A single injection of ASCs 
into the knee joints of mice 
with early-stage collagenase-
induced OA inhibited syno-
vial thickening, formation of 
enthesophytes associated 
with ligaments, and cartilage 
destruction.
Hatsushika et al13 2013 Rabbit Synovium was harvested from 
the knee joint of rabbits, and 
the colony-forming cells were 
collected. Two weeks after 
the anterior half of the medial 
menisci was excised in both 
knees, 1×107 MSCs in 100 μL 
PBS were injected into the right 
knee. MSC and control groups 
were compared macroscopi-
cally and histologically at 1, 3, 
4, and 6 months (n = 4).  
Articular cartilage of the medial 
femoral condyle was also 
evaluated histologically at 6 
months. Multipotentiality of 
the colony-forming cells was 
confirmed. Injected MSCs 
labeled with DiI were detected 
and remained in the meniscal 
defect at 14 days.
The meniscus was larger in the 
MSC group than in the control 
group at 1 and 3 months. The 
difference in size between the 
groups was indistinct at 4 and 
6 months. However, the histo-
logic score was better in the 
MSC group than in the control 
group at 1, 3, 4, and 6 months. 
Macroscopically, the surface 
of the medial femoral condyle 
was fibrillated in the control 
group but looked nearly intact 
in the MSC group at 6 months. 
Histologically, a defect or thin-
ning of the articular cartilage 
with sclerosis of the subchon-
dral bone was observed in the 
control group; contrarily, articu-
lar cartilage and subchondral 
bone were better preserved in 
the MSC group.
Synovial MSCs injected into 
the knee adhered around the 
meniscal defect and promoted 
meniscal regeneration in rab-
bits.
Park et al14 2013 Beagle Allogeneic adipose-derived 
canine MSCs were delivered 
to the regions of the lacrimal 
gland and the third eyelid gland 
and into the knee joints of 6 
healthy laboratory beagles as 
follows: 6 times with 1-week 
intervals for delivery to the lac-
rimal gland and the third eyelid 
gland regions and 3 to 4 times 
with 1- to 2-week intervals for 
intra-articular transplantations. 
The beagles were sequentially 
evaluated by clinical examina-
tion. At the end of the study, 
the beagles were humanely 
euthanized, and complete 
gross and histopathologic 
examinations of all organ sys-
tems were performed. Mixed 
leukocyte reactions were also 
performed before the first 
transplantation and after the 
final transplantation.
Clinical and pathologic exami-
nations revealed no severe 
consequences of repeated 
MSC transplantations. Results 
of mixed leukocyte reactions 
demonstrated suppression of 
T-cell proliferation after MSC 
transplantations.
Results of this study showed 
regional and systemic safety 
and systemic immunomodula-
tory effects of repeated local 
delivery of allogeneic MSCs 
in vivo.
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Nam et al15 2013 Boer goat Two full-thickness chondral 
defects 5 mm in diameter were 
created in tandem on the medi-
al condyle of the left stifle joints 
of 18 Boer goats, which were 
then divided into 3 groups of 
6. Simultaneously, bone mar-
row aspirates were taken from 
the iliac crests of the goats 
in group 1 and were sent for 
BM-MSC isolation and expan-
sion in vitro. Six weeks later, 
BMS surgery, which involves 
subchondral drilling at the 
defect sites, was performed. 
After 2 weeks, group 1 knees 
were given autologous intra-
articular BM-MSCs (n = 6). In 
group 2, though BMS surgery 
was performed, supplementa-
tions were not provided. In 
group 3, no intervention was 
administered. The goats were 
sacrificed after 6 months. 
Repairs were macroscopically 
assessed with ICRS scoring, 
histologic grading by O’Driscoll 
score, biochemical assays for 
glycosaminoglycans, and gene 
expressions for aggrecan, col-
lagen II, and Sox9.
Histologic and immunohisto-
chemical analyses revealed 
hyaline-like cartilage regenera-
tion in the transplanted sites, 
particularly in group 1. In 
contrast, tissues in groups 2 
and 3 showed mainly fibrocar-
tilage. The highest ICRS and 
O’Driscoll scorings were also 
observed in group 1; the lowest 
score was seen in group 3.  
Similarly, total glycosamino-
glycan/total protein as well as 
chondrogenic gene levels were 
expressed in the same order 
(highest in group 1, lowest in 
group 3). Significant differences 
were found between the 3 
groups.
Results of this study suggested 
that supplementing intra-articu-
lar injections of BM-MSCs after 
BMS surgery provides superior 
cartilage repair outcomes.
Abbreviations: ACL, anterior cruciate ligament; ASC, adipose-derived stem cell; BM, bone marrow stem cell cultured in basal media; BMS, bone marrow stimulation; BM-MSC, bone mar-
row–derived mesenchymal stem cells; BMSC, bone marrow stem cell; CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CM, chondrogenic-induced bone marrow stem cells;  
FBS, fetal bovine serum; FD, freeze drying; F12:DMEM, Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12; HA, hyaluronic acid; H&E, hematoxylin-eosin; ICRS, International Cartilage 
Repair Society; IGF-1, insulinlike growth factor 1; MSC, mesenchymal stem cell; OA, osteoarthritis; PBS, phosphate-buffered saline; TGF-β3, transforming growth factor β3.
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Varma et al16 2010 In this study, 50 patients with mild to 
moderate knee OA were selected and 
divided into 2 groups. Group A under-
went arthroscopic débridement, and 
group B had buffy coat (MSC con-
centrate) injection and arthroscopic 
débridement. On follow-up, patients 
were assessed on the basis of visual 
analog scale pain scores and OA out-
come scores to compare the groups’ 
results and determine the efficacy of 
arthroscopic injection of buffy coat in 
OA management.
The results suggested the technique 
used in the study considerably 
improved overall OA outcome scores, 
particularly QOL during and at the 
end of the studied follow-up period. 
The technique used in the study 
considerably improved overall OA 
outcome scores, particularly QOL 
during and at the end of the studied 
follow-up period. 
Wong et al17 2013 Fifty-six patients (56 knees) with uni-
compartmental knee OA and genu 
varum were randomly assigned to a 
cell-recipient group (n = 28) or a control 
group (n = 28). Exclusion criteria were 
joint-line congruity angle of >2°, knee 
malalignment from femoral causes, 
fixed flexion deformity, and age older 
than 55 years. All patients underwent 
HTO and microfracture. The cell-recipi-
ent group had intra-articular injection of 
cultured MSCs with HA 3 weeks after 
surgery. The control group received 
only HA. Primary outcome measure 
was IKDC score at 6 months, 1 year, 
and 2 years after surgery. Secondary 
outcome measures were Tegner and 
Lysholm clinical scores and 1-year 
postoperative MOCART scores.
Median age was 51 years. Mean 
body mass index was 23.85. Both 
treatment arms achieved improve-
ments in Tegner, Lysholm, and IKDC 
scores. After adjustment for age, 
baseline scores, and time of evalu-
ation, the cell-recipient group had 
significantly better scores. The effect 
of treatment showed added improve-
ment of 7.65 for IKDC scores, 7.61 for 
Lysholm scores, and 0.64 for Tegner 
scores. One year after surgical inter-
vention, MRIs showed significantly 
better MOCART scores for the cell-
recipient group. Age-adjusted mean 
difference in MOCART scores was 
19.6.
Intra-articular injection of cul-
tured MSCs was effective in improv-
ing short-term clinical and MOCART 
outcomes in patients who underwent 
HTO and microfracture for varus 
knees with cartilage defects.
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Davatchi  
et al19
2011 Four patients (ages, 55, 57, 65, 54 
years) with moderate to severe knee 
OA were selected for the study. After 
signed written consent was obtained, 
30 mL of bone marrow was taken 
and cultured for MSC growth. With 
enough MSCs in culture (4-5 weeks) 
and with all safety measures having 
been taken, cells were injected into 
1 knee of each patient.
Time spent walking before pain 
appeared improved for 3 patients and 
remained unchanged for 1. Number 
of stairs climbed and VAS pain scores 
improved for all patients. Physical 
examination revealed improvement 
was mainly for crepitus and improve-
ment in range of motion was minor.
Results were encouraging but not 
excellent. Improved technique may 
improve results.
Koh &  
Choi20
2012 Patients with knee OA had 25 
stem cell injections combined with 
arthroscopic débridement. A mean 
of 1.89×106 stem cells were prepared 
with approximately 3.0 mL of PRP 
and injected into selected knees of 
patients in the study group.
For the study group, mean Lysholm, 
Tegner, and VAS pain scores were 
significantly improved by final 
follow-up, and no major adverse 
events related to the injections were 
observed during the treatment and 
follow-up periods. Results for the 
study and control groups were com-
pared. Although the study group’s 
preoperative mean Lysholm, Tegner, 
and VAS pain scores were significant-
ly poorer than the control group’s, 
clinical results at final follow-up were 
similar and not significantly different 
between the groups.
The short-term results of this study 
are encouraging. They demonstrate 
that infrapatellar fat pad–derived MSC 
therapy with intra-articular injections 
is safe and assists in reducing pain 
and improving function in patients 
with knee OA.
Orozco  
et al21
2013 Twelve patients with chronic knee 
pain unresponsive to conservative 
treatments and with radiologic evi-
dence of OA were treated with autolo-
gous expanded bone marrow MSCs 
by intra-articular injection (40×10 
cells). Clinical outcomes, including 
pain, disability, and QOL, were fol-
lowed for 1 year. Quality of articular 
cartilage was assessed by quantita-
tive MRI T2 mapping.
Feasibility and safety were confirmed, 
and strong indications of clinical 
efficacy were identified. Patients 
exhibited rapid and progressive 
improvement (approaching 65%-78%) 
on algofunctional indices by 1 year. 
This outcome compares favorably 
with the results of conventional treat-
ments. In addition, quantification 
of cartilage quality by T2 relaxation 
measurements demonstrated a highly 
significant decrease in poor cartilage 
areas (mean, 27%), with improvement 
in cartilage quality in 11 of the 12 
patients.
MSC therapy may be a valid alterna-
tive treatment for chronic knee OA. 
The intervention is simple, does not 
require hospitalization or surgery, 
provides pain relief, and significantly 
improves cartilage quality.
Study Year Methods Results Conclusions
Saw et al18 2013 Fifty patients (ages 18-50 years) with 
ICRS grades 3 and 4 lesions of the 
knee joint underwent arthroscopic 
subchondral drilling; 25 were random-
ized to the intervention group (HA + 
PBSC) and 25 to the control group 
(HA). Both groups received 5 weekly 
injections starting 1 week after surgery. 
Three additional injections of either 
HA + PBSC or HA only were given 
at weekly intervals 6 months after 
surgery. Subjective IKDC scores and 
MRIs were obtained before surgery 
and at serial visits after surgery. At 18 
months, we performed second-look 
arthroscopy and biopsy on 16 patients 
in each group. We graded biopsy 
specimens using 14 ICRS II compo-
nents and obtained a total score. MRIs 
at 18 months were assessed with a 
morphologic scoring system.
Total ICRS II histologic scores aver-
aged 957 (control group) and 1066 
(intervention group), MRI morphologic 
scores averaged 8.5 (control) and 9.9 
(intervention), and mean 24-month 
IKDC scores were 71.1 (control) and 
74.8 (intervention). One patient was 
lost to follow-up. There were no 
notable adverse events.
After arthroscopic subchondral drill-
ing into grades 3 and 4 chondral 
lesions, postoperative intra-articular 
injections of autologous PBSCs com-
bined with HA resulted in improve-
ment in quality of articular cartilage 
repair, over that provided by the 
same treatment without PBSCs, as 
shown by histologic and MRI evalu-
ation.
Abbreviations: HA, hyaluronic acid; HTO, high tibial osteotomy; ICRS, International Cartilage Repair Society; ICRS II, ICRS Visual Assessment Scale II; IKDC, International Knee Documentat
ion Committee; MOCART, Magnetic Resonance Observation of Cartilage Repair Tissue; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; OA, osteoarthritis; PBSC, periph-
eral blood stem cell; QOL, quality of life.
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Koh  
et al22
2013 The study group had 18 patients (6 
men, 12 women). Mean age was 
54.6 years (range, 41-69 years). In 
each patient, adipose synovium was 
harvested from the inner side of the 
infrapatellar fat pad by skin incision 
extension at the arthroscopic lateral 
portal site after arthroscopic débride-
ment. After stem cells were isolated, 
a mean of 1.18×106 stem cells (range, 
0.3×106 to 2.7×106 stem cells) were 
prepared with approximately 3.0 mL 
of PRP (mean, 1.28×106 platelets/ μL) 
and injected into the selected knees. 
Clinical outcomes were evaluated 
with WOMAC and Lysholm scores 
and VAS pain scores. Also compared 
were MRI data collected both before 
surgery and at final follow-up.
WOMAC scores decreased sig-
nificantly (P < .001), from 49.9 points 
before surgery to 30.3 points at final 
follow-up (mean follow-up, 24.3 mo; 
range, 24-26 mo). Lysholm scores 
also improved significantly (P < .001) 
by final follow-up, increasing from a 
mean of 40.1 points before surgery to 
73.4 points by end of study. Likewise, 
there were significant (P = .005) 
changes in VAS pain scores through-
out the follow-up period. Mean VAS 
score decreased from 4.8 before 
surgery to 2.0 at final follow-up. 
Radiography showed that, at final 
follow-up, the whole-organ MRI score 
had significantly (P < .001) improved, 
from 60.0 points to 48.3 points. 
Particularly notable was the change 
in cartilage whole-organ MRI score, 
which improved from 28.3 points to 
21.7 points (P < .001). Further analysis 
revealed that improvements in clinical 
and MRI results were positively relat-
ed to number of stem cells injected.
The encouraging results of this study 
showed that intra-articular injection of 
infrapatellar fat pad–derived MSCs is 
effective in reducing pain and improv-
ing knee function in patients being 
treated for knee OA.
Koh  
et al23
2013 Stem cell injections combined with 
arthroscopic lavage were adminis-
tered to 30 elderly patients (≥65 years) 
with knee OA. Subcutaneous adipose 
tissue was harvested from both but-
tocks by liposuction. After stromal 
vascular fractions were isolated, a 
mean of 4.04×106 stem cells (9.7% 
of 4.16×107 stromal vascular frac-
tion cells) were prepared and injected 
into the selected knees of patients 
after arthroscopic lavage. Outcome 
measures included KOOS, VAS pain 
scores, and Lysholm scores before 
surgery and at 3-month, 12-month, 
and 2-year follow-up. Sixteen patients 
had second-look arthroscopy.
Almost all the patients had significant 
improvement in all clinical outcomes 
by final follow-up. All clinical results 
were significantly (P < .05) improved 
at 2-year versus 12-month follow-up. 
Of the patients older than 65 years, 
only 5 had worsening of Kellgren-
Lawrence grade. On second-look 
arthroscopy, 14 (87.5%) of 16 elderly 
patients improved or maintained 
cartilage status at least 2 years after 
surgery. Moreover, no patient under-
went total knee arthroplasty during 
this 2-year period.
ASC therapy for elderly patients with 
knee OA was effective in healing 
cartilage, reducing pain, and improv-
ing function. Therefore, ASC therapy 
seems to be a good treatment option 
for OA in elderly patients.
Jo et al24 2014 AD-MSCs were injected into the 
knees of 18 patients with knee OA. 
Phase 1 of the study had 3 dose-
escalation cohorts (3 patients 
each): low dose (1.0×107 cells), mid 
dose (5.0×107 cells), and high dose 
(1.0×108 cells). In phase 2, 9 patients 
were receiving the high dose. Primary 
outcomes were safety and WOMAC 
scores at 6 months. Secondary 
outcomes were clinical, radiologic, 
arthroscopic, and histologic evalua-
tions.
There were no treatment-related 
adverse events. WOMAC scores were 
improved in the high-dose group 6 
months after injection. Size of car-
tilage defect was decreased and 
volume of cartilage was increased in 
the medial femoral and medial tibial 
condyles of the high-dose group. 
Arthroscopy revealed decreased size 
of the cartilage defect in the medial 
femoral and medial tibial condyles 
of the high-dose group. Histology 
revealed thick, hyaline-like cartilage 
regeneration.
These results showed that intra-artic-
ular injection of 1.0×108 AD-MSCs into 
osteoarthritic knees improved func-
tion and pain in the knee joints 
without causing adverse events and 
reduced cartilage defects by regener-
ating hyaline-like articular cartilage.
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Gobbi et al25 2014 From January 2007 to February 2010, 
25 patients (mean age, 46.5 years) 
with symptomatic large chondral 
defects of the knee (ICRS grade 4) 
underwent cartilage transplantation 
with MSCs and a collagen type I/
III matrix. Minimum follow-up was 3 
years. Mean lesion size was 8.3 cm2. 
In 18 of these patients, coexisting 
injuries were treated concurrent with 
the surgery. All patients participated 
in a standard postoperative rehabili-
tation program. Several evaluations 
were done before surgery and at 1- 
and 2-year and final follow-up: radio-
graphs, MRI, and VAS pain, IKDC, 
KOOS, Lysholm, Marx, and Tegner 
scores. Seven patients had second-
look arthroscopic surgery, with 4 
consenting to tissue biopsy.
No patients were lost at final follow-
up. Mean (SD) preoperative scores 
were significantly (P < .001) improved 
at final follow-up: VAS pain improved 
from 5.4 (0.37) to 0.48 (0.19); IKDC 
subjective, from 37.92 (4.52) to 81.73 
(2.42); KOOS pain, from 61.04 (3.95) 
to 93.32 (1.92); KOOS symptoms, 
from 55.64 (3.23) to 89.32 (2.32); 
KOOS activities of daily living, from 
63.96 (4.48) to 91.20 (2.74); KOOS 
sports, from 34.20 (5.04) to 80.00 
(3.92); KOOS QOL, from 32.20 (4.43) 
to 83.04 (3.37); Lysholm, from 46.36 
(2.25) to 86.52 (2.73); Marx, from 3.00 
(0.79) to 9.04 (0.79); Tegner, from 
2.12 (0.32) to 5.64 (0.26). Patients 
younger than 45 years and patients 
with smaller or single lesions had 
better outcomes. MRIs showed 
good implant stability and complete 
filling of defect in 80% of patients. 
Histologic analysis of the biopsied tis-
sue revealed hyaline-like cartilage. No 
adverse reactions or postoperative 
complications were noted.
Large chondral defects can be effec-
tively treated with MSCs. This treat-
ment can be done routinely in clinical 
practice. Moreover, it can be achieved 
with 1-step surgery, avoiding a previ-
ous surgical procedure to harvest 
cartilage and subsequent chondro-
cyte cultivation.
Abbreviations: AD-MSC, adipose-derived mesenchymal stem cell; ASC, adipose-derived stem cell; ICRS, International Cartilage Repair Society; IKDC, International Knee Documentation  
Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; OA, osteoarthritis; PRP, platelet-rich plasma; QOL, 
quality of life; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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